ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
Provided By Globe Newswire
Last update: Nov 10, 2022
Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
